Iv'e seen companies with far less substance rise inexplicably on the ASX. It's a very strange experience seeing which ones rise and which ones don't.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
